Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy

British Journal of Haematology

Volumn 136, Issue 1, 2007, Pages 63-72

  Eichhorst, Barbara F ^a   Busch, Raymonde ^b   Schweighofer, Carmen ^a   Wendtner, Clemens M ^a   Emmerich, Berthold ^c   Hallek, Michael ^a,d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Chronic lymphocytic leukaemia; Fludarabine chemotherapy; Infections; Risk factors

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INCIDENCE; INFECTION; INFECTION RATE; INFECTION RISK; LEUKOPENIA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; SKIN INFECTION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 33845502293     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06382.x     Document Type: Article

References (45)

1. Anaissie, E.J., Kontoyiannis, D., O'Brien, S., Kantarjian, H., Robertson, L.B., Lerner, S. & Keating, M.J. (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Annals of Internal Medicine, 129, 559-566.
2. Bartik, M.M., Welker, D. & Kay, N.E. (1998) Impairments in immune cell function in B cell chronic lymphocytic leukemia. Seminars in Oncology, 25, 27-33.
3. Binet, J.L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., Thomas, M., Tchernia, G., Jacquillat, C., Boivin, P., Lesty, C., Duault, M.T., Monconduit, M., Belabbes, S. & Gremy, F. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, 198-206.
4. Borowski, B., Benhamou, E., Pico, J.L., Laplanche, A., Margainaud, J.P. & Hayat, M. (1994) Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. European Journal of Cancer. Part B, Oral Oncology, 30B, 93-97.
5. Bula, C.J., Ghilardi, G., Wietlisbach, V., Petignat, C. & Francioli, P. (2004) Infections and functional impairment in nursing home residents: a reciprocal relationship. Journal of the American Geriatrics Society, 52, 700-706.
6. Byrd, J.C., McGrail, L.H., Hospenthal, D.R., Howard, R.S., Dow, N.A. & Diehl, L.F. (1999) Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. British Journal of Haematology, 105, 445-447.
7. Cazin, B.D.M., Lepretre, S., Travade, P., Delmer, A., Jaubert, J., Lederlin, P., Dreyfuss, B., Leporrier, M., Harousseau, J., Grosbois, B., Maloisel, F., Eghbali, H., Dumontet, C., Guyot, D., Benichou, J., Guibon, O. (2002) Oral Fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukaemia (CLL): preliminary data on 75 patients. Blood, 100, abstract 773.
8. Cheson, B.D. (1995) Infectious and immunosuppressive complications of purine analog therapy. Journal of Clinical Oncology, 13, 2431-2448.
9. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
10. Cockcroft, D.W. & Gault, M.H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41.
11. Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P., Stuart, N., Rea, D., Bower, M., Fernando, I., Huddart, R., Gollins, S. & Stanley, A. (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. New England Journal of Medicine, 353, 988-998.
12. Di Raimondo, F., Giustolisi, R., Lerner, S., Cacciola, E., O'Brien, S., Kantarjian, H. & Keating, M.J. (2001) Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Annals of Oncology, 12, 621-625.
13. Eichhorst, B.F., Busch, R., Hopfinger, G., Pasold, R., Hensel, M., Steinbrecher, C., Siehl, S., Jager, U., Bergmann, M., Stilgenbauer, S., Schweighofer, C., Wendtner, C.M., Dohner, H., Brittinger, G., Emmerich, B. & Hallek, M. (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 107, 885-891.
14. Flinn, I.W., Byrd, J.C., Morrison, C., Jamison, J., Diehl, L.F., Murphy, T., Piantadosi, S., Seifter, E., Ambinder, R.F., Vogelsang, G. & Grever, M.R. (2000) Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood, 96, 71-75.
15. Flinn, I.W.B.J., Falkson, C.I., Flynn, P., Pundaleeka, S., Stadtmauer, E., Schnell, F., Grever, M., Tallman, M.S., Rowe, J.M. (2001) Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia: ECOG 1997. Blood, 98, abstract 2649.
16. Francis, S., Karanth, M., Pratt, G., Starczynski, J., Hooper, L., Fegan, C., Pepper, C., Valcarcel, D., Milligan, D.W. & Delgado, J. (2006) The effect of immunoglobulin V(H) gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer, 107, 1023-1033.
17. Griffiths, H., Lea, J., Bunch, C., Lee, M. & Chapel, H. (1992) Predictors of infection in chronic lymphocytic leukaemia (CLL). Clinical and Experimental Immunology, 89, 374-377.
18. Hallek, M., Wanders, L., Ostwald, M., Busch, R., Senekowitsch, R., Stern, S., Schick, H.D., Kuhn-Hallek, I. & Emmerich, B. (1996) Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leukemia and Lymphoma, 22, 439-447.
19. Hallek, M., Langenmayer, I., Nerl, C., Knauf, W., Dietzfelbinger, H., Adorf, D., Ostwald, M., Busch, R., Kuhn-Hallek, I., Thiel, E. & Emmerich, B. (1999) Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, non-smoldering chronic lymphocytic leukemia. Blood, 93, 1732-1737.
20. Hallek, M., Schmitt, B., Wilhelm, M., Busch, R., Krober, A., Fostitsch, H.P., Sezer, O., Herold, M., Knauf, W., Wendtner, C.M., Kuse, R., Freund, M., Franke, A., Schriever, F., Nerl, C., Dohner, H., Thiel, E., Hiddemann, W., Brittinger, G. & Emmerich, B. (2001) Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. British Journal of Haematology, 114, 342-348.
21. Itala, M., Helenius, H., Nikoskelainen, J. & Remes, K. (1992) Infections and serum IgG levels in patients with chronic lymphocytic leukemia. European Journal of Haematology, 48, 266-270.
22. Johnson, S., Smith, A.G., Loffler, H., Osby, E., Juliusson, G., Emmerich, B., Wyld, P.J. & Hiddemann, W. (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet, 347, 1432-1438.
23. Keating, M.J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E.J. & McCredie, K.B. (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 74, 19-25.
24. Keating, M.J., Kantarjian, H., O'Brien, S., Koller, C., Talpaz, M., Schachner, J., Childs, C.C., Freireich, E.J. & McCredie, K.B. (1991) Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. Journal of Clinical Oncology, 9, 44-49.
25. Keating, M.J., O'Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., Koller, C., Wierda, W., Detry, M.A., Lynn, A. & Kantarjian, H. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4079-4088.
26. Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. & Chastang, C. (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 98, 2319-2325.
27. Lovenich, H., Schutt-Gerowitt, H., Keulertz, C., Waldschmidt, D., Bethe, U., Sohngen, D. & Cornely, O.A. (2005) Failure of antiinfective mouth rinses and concomitant antibiotic prophylaxis to decrease oral mucosal colonization in autologous stem cell transplantation. Bone Marrow Transplantation, 35, 997-1001.
28. Martell, R.E., Peterson, B.L., Cohen, H.J., Petros, W.P., Rai, K.R., Morrison, V.A., Elias, L., Shepherd, L., Hines, J., Larson, R.A., Schiffer, C.A. & Hurwitz, H.I. (2002) Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemotherapy and Pharmacology, 50, 37-45.
29. Meisenberg, B., Gollard, R., Brehm, T., McMillan, R. & Miller, W. (1996) Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue. Supportive Care in Cancer, 4, 364-369.
30. Molica, S. (1994) Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leukemia and Lymphoma, 13, 203-214.
31. Molica, S., Levato, D. & Levato, L. (1993) Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica, 78, 374-377.
32. Morrison, V.A., Rai, K.R., Peterson, B.L., Kolitz, J.E., Elias, L., Appelbaum, F.R., Hines, J.D., Shepherd, L., Martell, R.E., Larson, R.A. & Schiffer, C.A. (2001) Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. Journal of Clinical Oncology, 19, 3611-3621.
33. O'Brien, S., Kantarjian, H., Beran, M., Smith, T., Koller, C., Estey, E., Robertson, L.E., Lerner, S. & Keating, M. (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood, 82, 1695-1700.
34. O'Brien, S., Kantarjian, H., Beran, M., Koller, C., Talpaz, M., Lerner, S. & Keating, M.J. (1997) Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia, 11, 1631-1635.
35. O'Brien, S.M., Kantarjian, H.M., Cortes, J., Beran, M., Koller, C.A., Giles, F.J., Lerner, S. & Keating, M. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 1414-1420.
36. Perkins, J.G., Flynn, J.M., Howard, R.S. & Byrd, J.C. (2002) Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer, 94, 2033-2039.
37. Pitten, F.A., Kiefer, T., Buth, C., Doelken, G. & Kramer, A. (2003) Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection, 53, 283-291.
38. Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N. & Pasternack, B.S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood, 46, 219-234.
39. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. & Schiffer, C.A. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1750-1757.
40. Rozman, C., Montserrat, E. & Vinolas, N. (1988) Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer, 61, 279-283.
41. Spitzer, W.O., Dobson, A.J., Hall, J., Chesterman, E., Levi, J., Shepherd, R., Battista, R.N. & Catchlove, B.R. (1981) Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. Journal of Chronic Disablity, 34, 585-597.
42. Tam, C.S., Wolf, M.M., Januszewicz, E.H., Grigg, A.P., Prince, H.M., Westerman, D. & Seymour, J.F. (2004) A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer, 101, 2042-2049.
43. Tsiodras, S., Samonis, G., Keating, M.J. & Kontoyiannis, D.P. (2000) Infection and immunity in chronic lymphocytic leukemia. Mayo Clinic Proceedings, 75, 1039-1054.
44. Wendtner, C.M., Ritgen, M., Schweighofer, C.D., Fingerle-Rowson, G., Campe, H., Jager, G., Eichhorst, B., Busch, R., Diem, H., Engert, A., Stilgenbauer, S., Dohner, H., Kneba, M., Emmerich, B. & Hallek, M. (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia, 18, 1093-1101.
45. Woo, P.C., Ng, W.F., Leung, H.C., Tsoi, H.W. & Yuen, K.Y. (2000) Clarithromycin attenuates cyclophosphamide-induced mucositis in mice. Pharmacological Research, 41, 527-532.